Testosterone Enanthate Missed-Dose Protocol: What to Do and Why It Matters

How Testosterone Enanthate Works: Mechanism of Action

Testosterone enanthate is a long-acting ester of testosterone that releases free testosterone after intramuscular injection. It acts primarily through androgen receptors (AR) in target tissues, driving changes in gene transcription that govern muscle protein synthesis, erythropoiesis, bone mineral density, libido, and mood. Understanding this mechanism is the foundation for understanding why dose timing matters.

Ester Hydrolysis and Free Testosterone Release

After injection into the gluteal or deltoid muscle, TE forms an oil-based depot in tissue. Plasma esterases cleave the enanthate ester over roughly 4 to 5 days, releasing free testosterone into the circulation. Pharmacokinetic modeling published in the Journal of Clinical Endocrinology and Metabolism shows that serum testosterone peaks within 24 to 72 hours of a 200 mg injection and then declines exponentially, with a half-life of approximately 4.5 days. By day 10 to 14, levels approach the pre-injection trough in weekly or biweekly dosing schemes.

Androgen Receptor Activation and Gene Transcription

Free testosterone crosses cell membranes and binds to the cytoplasmic androgen receptor. The testosterone-AR complex translocates to the nucleus, dimerizes, and binds to androgen response elements (ARE) on DNA. This drives transcription of genes encoding myosin heavy chain isoforms, erythropoietin receptor co-factors, and bone morphogenetic proteins. Research in the New England Journal of Medicine by Bhasin et al. demonstrated a dose-dependent relationship between serum testosterone concentration and lean body mass, with fat-free mass increasing by 3.2 kg at 600 mg/week over 20 weeks compared to placebo.

Aromatization to Estradiol

Roughly 0.3% of circulating testosterone is converted by aromatase (CYP19A1) to estradiol, primarily in adipose tissue, liver, and bone. Estradiol contributes to bone mineral density maintenance and cardiovascular homeostasis. A 2009 study in NEJM by Finkelstein et al. (N=198) showed that estrogen deficiency, not androgen deficiency alone, was responsible for most of the fat accumulation and much of the bone loss seen in hypogonadal men, which is why overly aggressive aromatase inhibition during TRT carries real risk.

Hypothalamic-Pituitary-Gonadal Axis Suppression

Exogenous testosterone suppresses LH and FSH through negative feedback on the hypothalamus and pituitary. In hypogonadal men on TRT, endogenous testicular testosterone production ceases within weeks. A trial published in the Journal of Clinical Endocrinology and Metabolism (Coviello et al., 2004) showed that even low-dose exogenous testosterone (25 mg/week) suppressed mean LH to near-zero. This suppression is why fertility preservation with gonadotropins (hCG, FSH) requires active management separate from the TE dose.

Testosterone Enanthate Missed-Dose Protocol: The Decision Tree

The missed-dose rule for TE is anchored in its half-life. Skip the dose too often and you induce cyclical hypogonadism; take double doses and you risk erythrocytosis, hypertension, and mood instability. The FDA-approved prescribing information for testosterone enanthate states that patients who miss a scheduled injection should administer the dose as soon as possible unless it is "almost time" for the next dose, in which case the missed dose should be skipped. The practical threshold depends on your dosing interval.

Weekly Dosing (Every 7 Days)

• Inject day (e.g., Monday): You miss your Monday injection.
• Remembered by Wednesday end of day (Day 1 to 2): Inject immediately. Shift future injections to the new day or return to Monday the following week.
• Remembered Thursday or Friday (Day 3 to 4): You are now within 50% of the next interval. Skip the missed dose. Inject on your normal Monday schedule.
• Remembered Saturday or Sunday (Day 5 to 6): Same rule. Skip entirely. Resume Monday.

The 50% cutoff corresponds to approximately 3.5 days for a 7-day schedule. At that point, your serum testosterone, though lower than peak, is still within or near the physiological range if your starting trough was adequate.

Biweekly Dosing (Every 14 Days)

• Remembered within 7 days of the missed dose: Inject immediately. Resume the 14-day cycle from the new injection date or return to the original schedule the following cycle.
• Remembered 8 to 13 days after the missed dose: Skip. Inject on your next scheduled date.

For biweekly dosing, trough levels drop more dramatically. Pharmacokinetic data from Behre et al. In the European Journal of Endocrinology showed that testosterone levels with biweekly 250 mg TE injections cycle from supraphysiological peaks (>1,200 ng/dL) down to sub-physiological troughs (<300 ng/dL) just before the next injection. Missing even one biweekly dose can leave a patient symptomatic for 3 to 5 days before the next scheduled injection. Transitioning to weekly dosing at half the biweekly dose eliminates this swing.

What "Double-Dose" Actually Means for Safety

A single double-dose event (e.g., 200 mg instead of 100 mg) will drive testosterone transiently above 1,500 ng/dL in most men. The Endocrine Society Clinical Practice Guideline (2018) sets the target range for testosterone replacement at 400 to 700 ng/dL (trough), with a general ceiling of 1,000 ng/dL. Levels above 1,000 ng/dL are associated with elevated hematocrit (target <54%), increased blood pressure, and acne. A single overshoot is rarely dangerous, but it reinforces a pattern of erratic dosing that compounds over time.

Clinical Evidence Supporting Testosterone Replacement Therapy

Understanding the efficacy data helps patients appreciate why consistent dosing matters. The T-Trials are the largest and most rigorous randomized controlled trial set evaluating testosterone therapy in older hypogonadal men.

The T-Trials (NEJM 2016)

The Testosterone Trials (T-Trials, N=790, NEJM 2016) randomized men 65 years and older with serum testosterone below 275 ng/dL to transdermal testosterone gel (targeting levels of 500 to 1,000 ng/dL) versus placebo for 12 months. The sexual function trial showed a statistically significant improvement in the Psychosexual Daily Questionnaire score (adjusted difference 2.64 points, P<0.001). The physical function trial showed a mean improvement of 27.6 meters in 6-minute walk distance in the testosterone group versus 13.7 meters in placebo (P=0.02). The vitality trial demonstrated improvement on the SF-36 vitality score (adjusted difference 2.41 points, P=0.03). While the T-Trials used gel rather than injections, the achieved serum testosterone levels are the same target for injectable TE.

Bone Mineral Density Data

The bone subcohort of the T-Trials (N=211) showed that testosterone increased volumetric bone mineral density in the spine by 7.5% (P<0.001) and trabecular bone score improved significantly, confirming that consistent therapeutic testosterone levels, not intermittent peaks and troughs, drive skeletal benefit.

Cardiovascular Considerations

The TRAVERSE trial (NEJM 2023, N=5,246) was a randomized, double-blind, placebo-controlled trial of testosterone gel in men 45 to 80 years old with hypogonadism and pre-existing or high cardiovascular risk. The primary MACE endpoint (cardiovascular death, myocardial infarction, stroke) was non-inferior to placebo (HR 0.96, 95% CI 0.78 to 1.17). This trial resolved a decade of uncertainty about TRT safety in high-risk patients. Atrial fibrillation and pulmonary embolism were slightly more frequent in the testosterone group, which reinforces the importance of avoiding supraphysiological surges from double-dosing or irregular administration.

Pharmacokinetics: Why Half-Life Drives the Protocol

The half-life of testosterone enanthate is the single most important number in missed-dose planning.

Half-Life Calculation in Practice

With a half-life of approximately 4.5 days, the concentration-time curve after a 100 mg dose follows first-order kinetics:

• Day 0 (injection): Peak approximately 700 to 900 ng/dL (serum total testosterone)
• Day 4.5: Approximately 350 to 450 ng/dL
• Day 9: Approximately 175 to 225 ng/dL
• Day 13.5 (3 half-lives): Approximately 87 to 112 ng/dL

This decline explains why men on weekly dosing who miss a single injection typically feel symptomatic by day 10 to 12 (fatigue, mood drops, low libido), as levels fall toward the hypogonadal threshold of 300 ng/dL. A pharmacokinetic review in Clinical Pharmacokinetics by Winters (1990) remains the foundational reference for TE half-life estimation.

Volume of Distribution and Binding Proteins

Approximately 44% of circulating testosterone is bound to sex hormone-binding globulin (SHBG), 54% to albumin, and only 1 to 2% is free (bioactive). Data from the Endocrine Society's position paper on testosterone measurement (2017) recommends measuring total testosterone in the morning before an injection (trough) to standardize comparisons between visits, as SHBG levels vary substantially by age, BMI, and comorbidities.

Steady State and Accumulation

With once-weekly dosing, steady-state testosterone levels are reached after approximately 4 to 5 half-lives, or roughly 3 to 4 weeks. Pharmacokinetic modeling by Swerdloff et al. shows that the peak-to-trough ratio narrows as steady state is approached. Consistent weekly dosing produces mean trough levels approximately 20 to 30% higher than after the first injection, which is why clinicians typically wait until week 6 to 8 before adjusting the dose based on trough labs.

Injection Technique: Variables That Affect Absorption

Even with perfect timing, absorption varies with injection technique.

Injection Site Selection

The gluteus medius (ventrogluteal site) and vastus lateralis (thigh) are the preferred sites per CDC immunization and injection guidelines, which apply to IM injections broadly. The dorsogluteal site carries a higher risk of sciatic nerve proximity and has been largely abandoned in modern practice. The deltoid is acceptable for volumes up to 1 mL. For the typical 1 mL TE dose (100 mg/mL formulation), the ventrogluteal or vastus lateralis is preferred.

Needle Length and Gauge

Subcutaneous injection of an oil-based depot results in slower, more variable absorption compared to true IM delivery. Research published in BMJ by Nisbet et al. showed that needle length of 38 mm (1.5 inches) reaches IM tissue in the vast majority of adults, while 25 mm (1 inch) may fail to reach muscle in individuals with BMI >30. A 21 to 23 gauge needle balances viscosity of the oil vehicle against patient discomfort.

Aspiration: Current Guidance

The WHO and CDC no longer recommend aspiration before IM injections in non-vascular sites. The WHO's 2015 best-practices guidance for injection technique states that aspiration is unnecessary and increases pain without adding safety. This applies to testosterone IM injections given in the ventrogluteal or thigh sites.

Monitoring Schedule for Patients on Testosterone Enanthate

Consistent dose timing is only one part of safe TRT. Laboratory monitoring catches problems before they become clinically significant.

Baseline Labs Before Starting TE

Per the Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism, baseline labs before initiating testosterone therapy must include:

• Total testosterone (two morning samples on separate days, each below 300 ng/dL to confirm hypogonadism)
• LH and FSH (to differentiate primary vs. Secondary hypogonadism)
• Complete blood count (hematocrit baseline)
• PSA (men 40+ at average risk; 35+ at elevated risk)
• Lipid panel
• Estradiol (sensitive LC-MS/MS assay preferred)

On-Treatment Monitoring

• 3 months after initiation: Trough testosterone, hematocrit, PSA.
• 6 months: Repeat the above; add bone density scan (DEXA) if osteoporosis was a baseline concern.
• Annually once stable: Full panel including liver function, lipids, metabolic panel.

The American Urological Association's 2022 testosterone deficiency guidelines recommend holding or dose-reducing TE if hematocrit exceeds 54%, as erythrocytosis increases whole-blood viscosity and thrombotic risk. This threshold is particularly relevant after a period of double-dosing or irregular administration.

When to Draw the Lab: Trough vs. Peak

Draw trough labs (just before the next scheduled injection) rather than peak labs for clinical decisions. A 2017 analysis in the Journal of Sexual Medicine by Ramasamy et al. found that peak testosterone measurements taken 24 to 48 hours post-injection frequently exceeded 1,500 ng/dL in men on 200 mg biweekly dosing, even when troughs were within range. Trough measurements reflect the clinically meaningful minimum and avoid falsely reassuring peak values.

Special Populations: Adjusted Protocols

Men Transitioning From Biweekly to Weekly Dosing

Transitioning from 200 mg every 14 days to 100 mg every 7 days requires no "loading" adjustment. The dose per unit time is identical. Serum testosterone levels will be more stable within 2 to 3 weeks of the switch. A crossover pharmacokinetic study in the Journal of Clinical Endocrinology and Metabolism (Snyder et al., 2000) showed that peak-to-trough variability dropped by approximately 40% when the same total weekly dose was split across more frequent injections.

Gender-Affirming Hormone Therapy (Transgender Men)

TE is commonly used off-label for masculinizing hormone therapy. The Endocrine Society's 2017 Clinical Practice Guideline on gender-dysphoric/gender-incongruent persons recommends target testosterone levels in the male physiological range (400 to 700 ng/dL trough). The missed-dose protocol is identical to that for cisgender hypogonadal men: inject as soon as remembered if more than 50% of the dosing interval remains; otherwise, skip and resume schedule.

Older Men (65+)

The T-Trials enrolled men with a mean age of 72 and a mean baseline testosterone of 232 ng/dL. Older men metabolize testosterone more slowly due to lower lean body mass and reduced hepatic esterase activity, which can modestly extend the effective half-life. A sub-analysis of T-Trials pharmacokinetics published in JCEM showed that achieving mid-normal testosterone levels (500 to 600 ng/dL) required lower doses in men 75+ compared to men 65 to 74. Missed doses in this population may cause less acute symptomatic decline, but the long-term risks of sustained sub-therapeutic levels (bone loss, anemia, falls) remain the same.

Practical Patient Instructions

Clear, numbered guidance reduces errors at home.

1. Set a recurring alarm on your phone for your injection day (e.g., every Monday morning).
2. If you forget on Monday, check the day: inject immediately if it is Tuesday or Wednesday. Skip if it is Thursday or later. Resume next Monday.
3. On a biweekly schedule, inject immediately if within 7 days of the missed dose. Skip if 8 or more days have passed.
4. Never inject double the dose. A single extra injection can raise testosterone above 1,500 ng/dL and increase hematocrit acutely.
5. Document the missed dose and disclose it at your next lab draw. Trough labs drawn in a week following a skip dose will be artificially low and may prompt an unnecessary dose increase.
6. Call your prescriber if you miss two or more consecutive doses, as your monitoring schedule and next lab draw timing may need adjustment.

Frequently Asked Questions